Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2016-01-04 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
独立董事关于为关联方提供对外担保暨关联交易事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on a related party external guarantee and related transaction matter, referencing regulatory guidelines and company governance rules. It is a formal statement or opinion rather than a full report or financial statement. The document length is short (514 characters), and it does not contain financial data or detailed report content. It is not an announcement of voting results, nor a management or audit report. It fits best as a Regulatory Filing (RNS) because it is a compliance-related disclosure that does not fit other specific categories.
2016-01-04 Chinese
关于股票复牌的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the resumption of trading (stock resumption) after a suspension due to an inquiry from the Shanghai Stock Exchange. It references prior announcements and regulatory communications but does not contain financial statements, detailed financial data, or management discussion. The document length is only 507 characters, indicating it is a brief notice rather than a full report. It is an official announcement about stock resumption, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other more specific categories like Capital/Financing Update or Delisting Announcement.
2015-12-31 Chinese
关于对上海证券交易所问询函回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shanghai Stock Exchange regarding the company's external investment matters, specifically about the research and development status, clinical application, legal and regulatory environment, cooperation plans, and risk disclosures related to immunotherapy technologies such as CAR-T, PD1, gp96, and IL-15. It includes extensive technical and regulatory information, risk warnings, and future plans but does not present financial statements or quarterly/yearly financial results. The document is not a report publication announcement since it contains substantive content rather than just announcing a report's release. It is not a certification or attestation letter. The content is regulatory in nature, responding to a regulatory inquiry, and thus fits best under Regulatory Filings (RNS).
2015-12-31 Chinese
关于收到上海证券交易所问询函及公司股票停牌的提示性公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from a company regarding receipt of an inquiry letter from the Shanghai Stock Exchange about an external investment and the subsequent suspension of the company's stock trading. It details the content of the inquiry, requests for additional disclosures, and the company's response including the stock suspension. The document is short (2141 characters) and serves as a regulatory announcement about the inquiry and stock suspension, not a full report or detailed financial disclosure. It does not contain financial statements, earnings data, or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document.
2015-12-30 Chinese
对外投资公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by the company 中源协和细胞基因工程股份有限公司 regarding an external investment to establish a new company, 英威福赛生物技术有限公司. It details the investment amount, the cooperation agreement, board meeting approval, and risk analysis related to the investment. There are no financial statements, quarterly or annual results, audit opinions, or regulatory certifications. The document is a formal announcement of a corporate action (investment) rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a management change announcement or voting result. The content is about capital investment and company formation, which aligns with Capital/Financing Update (CAP). The document length is 3499 characters, which is sufficient for a detailed announcement. Therefore, the best classification is Capital/Financing Update (CAP).
2015-12-29 Chinese
融资融券业务管理细则
Governance Information Classification · 95% confidence The document is titled as a management rule or internal regulation regarding the company's margin financing and securities lending business. It outlines the company's internal policies, approval authorities, operational procedures, and risk management related to financing and securities lending activities. It does not contain financial statements, audit opinions, earnings data, or shareholder meeting materials. It is a governance-related internal management document rather than a report or announcement to external stakeholders. Therefore, it best fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices.
2015-12-28 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.